If you have been reading about Drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-13. Numbers and descriptions here follow the published literature rather than marketing material.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The nuclear properties of plutonium-239 were also studied; researchers found that when it is hit by a neutron it breaks apart (fissions) by releasing more neutrons and energy. These neutrons can hit other atoms of plutonium-239 and so on in an exponentially fast chain reaction. This can result in an explosion large enough to destroy a city if enough of the isotope is concentrated to form a critical mass. During the early stages of research, animals were used to study the effects of radioactive substances on health. These studies began in 1944 at the University of California at Berkeley's Radiation Laboratory and were conducted by Joseph G. Hamilton. Hamilton was looking to answer questions about how plutonium would vary in the body depending on exposure mode (oral ingestion, inhalation, absorption through skin), retention rates, and how plutonium would be fixed in tissues and distributed among the various organs. Hamilton started administering soluble microgram portions of plutonium-239 compounds to rats using different valence states and different methods of introducing the plutonium (oral, intravenous, etc.). Eventually, the lab at Chicago also conducted its own plutonium injection experiments using different animals such as mice, rabbits, fish, and even dogs. The results of the studies at Berkeley and Chicago showed that plutonium's physiological behavior differed significantly from that of radium. The most alarming result was that there was significant deposition of plutonium in the liver and in the "actively metabolizing" portion of bone.
One factor that has an important effect on this electrical activity of gonadotrophs is the gonadotropin-releasing hormone (GnRH). GnRH is a hormone released by the hypothalamus, and it is responsible for signaling gonadotrophs to release gonadotropins FSH and LH. GnRH binds to gonadotropin-releasing hormone receptors (GnRHR), which is a G-protein coupled receptor, and signals the oscillation of calcium that hyperpolarizes gonadotropic cell membranes. This oscillation of calcium ions occurs through the resultant signaling cascade of the GnRH binding to the GnRHR in the plasma membrane of the gonadotroph. The G-protein associated with the GnRHR is activated by the binding of GnRH, which results in increased phospholipase C (PLC) activity in the plasma membrane. PLC cleaves phosphatidylinositol-4,5-biophosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG) signals. DAG activates protein kinase C (PKC), which phosphorylates proteins, and IP3 binds to IP3 receptors on the membrane of the endoplasmic reticulum (ER). This binding results in the release of intracellular calcium ions stored within the ER. Therefore, this increase in calcium ions signals the synthesis of secretion of FSH and LH in gonadotrophs. Overall, the fluctuation of calcium levels that is activated by the electrical activity and the signaling pathway within gonadotropic cells collectively contribute to the synthesis and release of gonadotropins that will serve an endocrine function in the reproductive system.
== Legacy and later life == Singh's structured administration is credited with slowing India's rate of deforestation between 1960 and 1980 by introducing professional oversight and improving legal frameworks against illegal logging. After retiring from the civil service in 1969, he served as a Professor Emeritus at the Forest Research Institute and College for a five-year term, and later as the Managing Director of the Newsprint Paper and Pulp Mills in Nepanagar, Madhya Pradesh. His contributions were commemorated during his birth centenary in 2010 with the release of a biographical book, Hari Singh: A Life Sketch, and the establishment of the Hari Singh Fellowship at the Indira Gandhi National Forest Academy to honour outstanding IFS probationers. Singh was married and had at least one son, Dr. Subir Hari Singh. He passed away in 2003 at the age of 93.
Sources: en.wikipedia.org
=== Genetic engineering === Magnetic nanoparticles can be used for a variety of genetics applications. One application is the rapid isolation of DNA and mRNA. In one application, the magnetic bead is attached to a poly T tail. When mixed with mRNA, the poly A tail of the mRNA will attach to the bead's poly T tail and the isolation takes place simply by placing a magnet on the side of the tube and pouring out the liquid. Magnetic beads have also been used in plasmid assembly. Rapid genetic circuit construction has been achieved by the sequential addition of genes onto a growing genetic chain, using nanobeads as an anchor. This method has been shown to be much faster than previous methods, taking less than an hour to create functional multi-gene constructs in vitro.
== Formulation == Aulus Cornelius Celsus details one version of the antidote in De Medicina (ca. AD 30). A recent translation is as follows: "But the most famous antidote is that of Mithridates, which that king is said to have taken daily and by it to have rendered his body safe against danger from poison". It contained:
== Function == Produced mainly in the liver, plasminogen is the inactive zymogen form of plasmin, and circulates in plasma in a closed conformation that cannot be activated. Binding clots or cell surfaces cause their conformation to change, allowing them to be activated by plasminogen activators. Plasminogen activators do so by cleaving the R561/V562 peptide bond, producing the active protein plasmin, which catalyzes the degradation of fibrin polymers that make up the structure of blood clots.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.